What should the optimal target hemoglobin be? Partial correcworsens as renal function declines, such that when creatition of anemia in patients with chronic kidney disease (CKD) nine clearance is below 25 mL/min, the prevalence of improves anemia-related symptoms. However, controversy reanemia is approximately 87% [1]. These findings suggest mains as to whether total correction of anemia provides benethat patients with CKD may be anemic for a long time fits over and above those afforded by partial correction. There is some evidence showing that normalization of hemoglobin during the progression of the disease. If this is the case, (Hb) concentrations may improve the cardiac hyperdynamic then patients are exposed to an important risk factor state in CKD patients and reduce the diameter of the left that could influence clinical outcomes.
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ventricle. Further studies have shown that normalization of As oxygen supply to the tissues decreases due to ane-Hb improves cognitive function and physical capacities as meamia, several compensatory mechanisms develop, includsured by quality of life (QoL) tests. Large studies have shown that in dialysis patients there is a close inverse relationship ing cardiovascular adaptations [2] . Owing to these sysbetween hematocrit (Hct) levels and mortality and morbidity. tems of adaptation, anemia is largely responsible for the Moreover, there is evidence suggesting that Hct levels higher significant detrimental cardiac effects occurring in CKD than those recommended by European Best Practice Guidepatients (Table 1) target Hb that includes the provision to normalize Hb. However, some recent studies have reached controversial conclusions on the benefits of normalizing Hb con-Anemia is a very frequent complication in patients with centrations. On the one hand, some authors have witchronic kidney disease (CKD). It affects over 90% of nessed an increase in the beneficial effects of anemia patients undergoing renal replacement therapy with dialtherapy when Hb is normalized [5-8] while other authors ysis, but it may begin in the early stages of renal insuffihave experienced conflicting results in selected groups ciency, well before the initiation of dialysis. The prevaof patients [9] . The aim of this review is to summarize lence of anemia in CKD correlates inversely with the advantages and disadvantages of normalizing Hb residual renal function. In the Canadian multi-center levels in CKD patients. study of renal anemia, the prevalence of anemia was found to be approximately 25% when creatinine clearance is higher than 50 mL/min. Anemia progressively [18] . A multi-center Spanish study of 102 pre-dialysis patients showed that partial correction of anemia (Hb from 9 to 11 g/dL) resulted in a decrease in left ventricular mass index at 6 months. The most promising effect was in patients without basal LVH who of the left ventricle (eccentric LVH), where the diameter/ wall thickness ratio remains constant.
EVIDENCE IN FAVOR OF A NORMAL TARGET HEMOGLOBIN
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remained normal when treated with epoetin, while nontreated patients experienced increased left ventricular From the very first clinical experiences with epoetin, various studies have shown that partial correction of ane-mass (abstract; Valderrá bano et al, Nephrol Dial Transplant 15:A114, 2000. These data suggest, once again, that mia is accompanied by the partial regression of LVH [10] [11] [12] [13] . However, these studies were conducted on rela-early anemia correction protects against the development of LVH. tively small groups of patients, and did not aim to fully normalize Hb concentrations. A Spanish multi-center An observational study of 4866 pre-dialysis patients was recently published by Fink et al, showing that the study of 91 hemodialysis patients has also shown that the increase in Hb concentrations with epoetin reduces mortality risk after initiating dialysis was lower for patients treated with epoetin before dialysis compared with the severity of LVH. This improvement is due to a significant decrease in left ventricular diameter, but the patients who were not treated. However, there was no relationship between pre-dialysis Hct and mortality rate, overall thickness of the left ventricular walls does not change (abstract; Ló pez Gó mez et al, J Am Soc Nephrol suggesting that epoetin therapy prior to dialysis confers an increased probability of survival when the patients 11:A1488, 2000.
It is unclear whether Hb normalization may have an reach end-stage renal disease (ESRD) [20] . Thus, it seems that correction of anemia must be initiated early in the added advantage to such patients. The Canadian multicenter study has shown that complete correction of ane-progression of CKD, and that complete correction may add complementary beneficial effects. However, new tri-mia fails to induce regression of well established concentric LVH or left ventricular dilation, but it appears to als are necessary to confirm this hypothesis. Accordingly, several studies currently underway in Australia, Canada, prevent left ventricular dilation in patients with normal left ventricular volume [15] . However, in a prospective, and the UK, which, along with the Cardiovascular Risk reduction by Early Anemia Treatment with Epoetin beta randomized, and doubled-blind cross-over study of 14 hemodialysis patients, Hb normalization was followed (CREATE) trial [21] , are attempting to assess the effect of earlier anemia treatment on cardiac function. The by a reduction in left ventricle end diastolic diameter with a 5% reduction in left ventricular mass index that results are promising and could show clear evidence of the preventive effect of early anemia correction in LVH was not statistically significant [8] .
The US Normal Hemocrit Trial showed that complete and cardiovascular morbidity. They could also answer the question of whether or not achieving normal target correction of anemia in hemodialysis patients with symptomatic heart failure or ischemic heart disease was associ-Hb concentrations has beneficial effects on long-term outcomes for CKD patients. ated with a trend towards higher mortality rates compared with similar patients in the low target Hct group Cognitive function [9] . These studies suggest that when there are important alterations in cardiac structures, the beneficial effect of Various studies using different neuropsychological and neurophysiological tests in dialysis patients have the total correction of anemia is very limited, although the results of the Canadian study have shown a favorable demonstrated that raising Hb/Hct to the levels recommended by the EBPG (Hb Ն11 g/dL in Ն85% of patients effect on the prevention of LVH once the developing anemia is corrected.
with uncomplicated anemia) [3] and the NKF-DOQI Guidelines (Hct between 33% and 36%) [4] is accompa-LVH may be evident very early in the progression of CKD [16] . The US and Canadian data combined suggest nied by an improvement in cognitive function [22] [23] [24] and in electroencephalogram (EEG) characteristics [22, 25] . that the prevention of structural heart changes should be initiated early, i.e., in the pre-dialysis phase. However, Metry et al suggest that maximal level of oxygen deliv-
S-41
ery to the brain occurs when Hct levels are higher than are believed to be the most apparent. A comparison of very anemic patients with those treated to levels recom-36% [26] . This hypothesis brings once more to the fore the question: does normalizing Hb concentrations have mended by the EBPG [3] and NKF-DOQI [4] (Hb 11-12 g/dL) shows that the QoL scores are strongly re-benefits additional to achieving existing agreed targets? To this end, Pickett et al studied the effects of raising lated to Hb concentrations [38] . However, an aspect that is not so well studied is the evaluation of QoL when Hb Hct from 31.6% to 42.8% in a group of 20 hemodialysis patients. EEGs revealed significant improvement, and im-concentrations reach normal values. The US Normal Hematocrit Trial showed that physical function, assessed provement was also shown in electrophysiological tests mainly affecting P300 latency and amplitude [7] .
by SF-36 questionnaire increased 0.6 points for each percentage point increase in Hct [9] . In the Canadian A study of the effects of epoetin therapy on sleep, sleep disorders, and daytime sleepiness on hemodialysis multi-center study, fatigue, depression, and relationship capacities improved significantly when normal Hb con-patients (the SLEEPO trial), conducted by Benz et al showed that after increasing mean Hct from 32.3% to centrations were achieved [15] . The Spanish Co-operative Renal Patients QoL Study Group examined the ef-42.3%, some parameters of quality of sleep such as periodic leg movement, arousing periodic limb movements fect on the QoL and functional status in 156 hemodialysis patients after achieving an Hct close to normal. After in-in sleep (PLMS), or maintenance wakefulness assessed by polysomnography were significantly improved (ab-creasing the epoetin dose by approximately 50%, QoL was measured using the Sickness Impact Profile (SIP) and stract; J Am Soc Nephrol 7:1473, 1996. These results suggest that normalization of Hct may have an added functional status was measured using the Karnofsky scale.
The results show that normalized Hct is associated with beneficial effect on improving cognitive function and the quality of sleep in dialysis patients.
an improvement in physical and psychosocial scores as well as in the mean global SIP score and functional status.
Physical function
No adverse effects of epoetin therapy were observed [6]. Similar results were found in the Australian study [8] . Anemia therapy with epoetin results in an increase in working capacity and aerobic exercise [13, 28, 29] as the Mortality and morbidity result of an increased transport of oxygen to the muscular tissue. Suzuki et al show that the VO 2 is higher at a Hct Anemia has been shown to be a predictive risk factor of mortality and morbidity [39] [40] [41] . In a Canadian study level of 35-40% than at 30% [30] . In a multi-center study of 11 pre-dialysis patients, greater improvement of dialysis patients, each 1 g/dL decrease in Hb concentration was independently associated with an improve-in energy and work capacity was observed when Hct was increased from 28% to 38%. In these patients, oxygen ment in the relative risk of death of 1.14 [39] . Ma et al studied the relationship between mortality and Hct in a consumption at anaerobic threshold and at maximal exercise capacity increased, but did not reach normal val-group of 75,283 Medicare patients and found that the relative risk of death decreased in patients with increased ues. This suggests that poor physical performance in renal patients is not only due to anemia, but that other Hct. All causes of death (including cardiac causes) in diabetic and non-diabetic patients were found to be at factors such as neuropathy, cardiovascular disease, and poor conditioning may also contribute [31] .
the lowest incidence when Hct levels were in the range 33-36% [40] . In the study by Besarab of 1233 hemodialy-The effect of different Hb concentrations on maximal exercise performance has also been studied in 14 hemo-sis patients with cardiac disease, patients in whom Hct was increased to normal levels (42 Ϯ 3%) had higher dialysis patients. The results show that peak work rate and peak VO 2 significantly increase after normalization rates of mortality than the control group (Hct 30 Ϯ 3%). However, this study included only patients with of Hb with no difference observed between young and older patients [32] .
congestive heart failure or ischemic heart diseases and deaths were due to cardiovascular causes [9] . The study Quality of life has been analyzed and criticized in two interesting editorials [42, 43] . In recent years, the evaluation of health-related QoL has emerged as an important and useful tool for studying In a Medicare dialysis cohort of 71,717 patients, the probability of hospitalization was found to be less when the efficacy and net benefit of medical therapies. In ESRD patients, QoL has been shown to be worse than Hct levels were in the range 33-36% than when Hct levels were lower [41] . Our co-operative Spanish group that of the general population and anemia has been implicated as one of the main related factors [33] .
has also studied the effect of Hct Ͼ36% on hospitalization rates. It showed a significant decrease in the number The partial correction of anemia with epoetin is accompanied by an improvement in the QoL in both pre-of hospitalized patients and hospitalization length when Hct was normalized [6]. More recently, Collins et al have dialysis [34] and dialysis [35] [36] [37] patients, and the aspects related to the physical dimension of the QoL score performed a retrospective study with incident hemodial-
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ysis patients with Medicare insurance. The authors show 51% [6] , whereas in the Besarab study, the mean dose of epoetin increased by approximately 200% [9] . that for those patients with Hct Ͼ36%, hospitalization rates were 16-22% lower than in the rest of the patients. However, the relative risk of death was not different
OPTIMIZATION OF EPOETIN THERAPY between patients with Hct values of 36-39% compared
Currently, there is strong evidence that total correcwith those with values of 33-36% [44] . tion of anemia by normalizing Hb concentrations offers In summary, partial correction of anemia in ESRD clear benefits in selected patients with CKD. It no longer patients has a beneficial effect on mortality and morbidseems reasonable to allow the development of anemia ity, but complete correction may provide further imand its deleterious effects on these patients. Thus, the provements in some selected patients.
most appropriate target Hb concentration should be correction to normal levels. The main concerns over this POTENTIAL ADVERSE EFFECTS OF A objective include the high costs and possible adverse NORMAL TARGET Hb effects on selected groups of patients. Consequently, the recommendation of normalizing Hb is not appropriate High Hb concentrations increases blood viscosity and for all dialysis patients and the target Hb should be may potentially play a role in the coagulation and thromtailored to the clinical conditions of each individual pabosis of vascular access for hemodialysis. Very few studtient, bearing in mind his/her age, sex, physical activity, ies have evaluated the role that normalization of Hct dialysis modality, and co-morbidity factors. As Macdoumay have on vascular access. During a mean follow-up gall suggests, a normal Hb may be appropriate for young period of 49 months, the US Normal Hct Trial showed patients, in full-time employment, physically active, and that high Hct levels are not associated with greater inciwith no severe co-morbidity, whereas partial correction dence of vascular access thrombosis [9] . Thrombosis of of anemia would be reserved for elderly patients with vascular access was evaluated during the 6-month period significant co-morbidities [49] . of the Spanish co-operative study on the normalization of Overall, we are seeing greater evidence as to the need the Hct. This study found that 5.7% of patients suffered a to begin treatment with epoetin in the early stages of thrombosis of the vascular access. The cumulative vascu-CKD, which has the potential to prevent anemia and its lar access survival at 6 months (CI 95%) was 0.93 Ϯ 0.04. cardiovascular complications. To initiate therapy when Even though the complications of the vascular accesses Hb levels fall below 11 g/dL is probably too late. By then, are very different between centers, making comparisons many patients will have severe, irreversible LVH as well as between them difficult, it does not seem that correctother complications due to the effect of prolonged anemia. ing anemia has a detrimental effect on vascular access [45] [46] [47] . However, studies specially designed to research 
